



REPUBLIC OF THE PHILIPPINES  
DEPARTMENT OF FINANCE  
BUREAU OF INTERNAL REVENUE

JAN 26 2024

REVENUE MEMORANDUM CIRCULAR NO. 17-2024

**SUBJECT :** Publishing the Full Text of the November 29, 2023 Letter from the Food and Drug Administration (FDA) of the Department of Health (DOH) Endorsing Updates to the List of VAT-Exempt Products Under Republic Act (R.A.) No. 10963 (TRAIN Law) and R.A. No. 11534 (CREATE Act)

**TO :** All Internal Revenue Officers and Others Concerned

For the information and guidance of all internal revenue officers, employees and others concerned, attached is the November 29, 2023 letter (Annex "A") from Dr. Samuel A. Zacate, Director General of the FDA, for an update to the published List of VAT-Exempt Medicines Under R.A. No. 11534 or the CREATE Act, particularly the following:

1. Inclusion of certain medicines for cancer, diabetes, hypertension, kidney disease, mental illness, and tuberculosis; and
2. Deletion of medicine for hypertension.

As clarified under Q&A No. 1 of RMC No. 99-2021, the effectivity of the VAT exemption of the covered medicines and medical devices under the CREATE Act shall be on the date of publication by the FDA of the updates to the said list.

All concerned are hereby enjoined to be guided accordingly and give this Circular as wide a publicity as possible.



*Romeo D. Lumagui, Jr.*  
ROMEO D. LUMAGUI, JR.  
Commissioner of Internal Revenue

